drugset / Trial / NCT05369364
The Combination of Zanubrutinib and High-dose Dexamethasone as First-line Treatment in Adult Immune Thrombocytopenia
Phase 2
Unknown
150 enrolled
Peking University People's Hospital
Beijing Aerospace General Hospital · collabBeijing Hospital · collabBeijing Tongren Hospital · collabNavy General Hospital, Beijing · collabQilu Hospital of Shandong University · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
Randomized, open-label, multicenter study to compare the efficacy and safety of zanubrutinib plus high-dose dexamethasone compared to high-dose dexamethasone monotherapy for the first-line treatment of adults with primary immune thrombocytopenia (ITP).
Timeline
- Start
- 2022-06-01
- Primary completion
- 2025-12-30
- Completion
- 2026-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Zanubrutinib | Small molecule | 80 mg | Oral |
| Background | Dexamethasone | Small molecule | 40 mg | Intravenous |